Built on our proprietary technologies and workflows, our research services platforms and applications provide actionable insights on protein expression, function, and structure. Our industry-leading proteome depth and sample throughput enable simultaneous quantification of thousands of proteins across thousands of samples in a single study. No matter what the objectives of your research are, our proprietary platforms allow industry-leading, highly sensitive, and precise proteome quantification to advance your projects with transformative insights from discovery to clinic.
The Biognosys TrueDiscovery® platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluid proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GCP compliant environment.
The Biognosys TrueSignature® platform provides customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring with exceptional precision.
Parallel Reaction Monitoring (PRM) and SureQuant mass spectrometry power the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature panels offer versatile protein combination options, including single proteins, multiplex panels, and hyperplex panels of up to 800 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies help guide the selection of peptides in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys’ state-of-the-art facility, one of the world’s largest high-end GCP-compliant mass spectrometry laboratory.
The Biognosys TrueTarget® platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis coupled to Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.
The platform enables elucidating mechanisms of action and revealing unanticipated toxicities.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
